RegulatoryMay 29, 2026, 05:02 PM
Sinovac Receives Nasdaq Delist Notice for Late 2025 Annual Report
AI Summary
Sinovac Biotech Ltd. announced it received a delist determination letter from Nasdaq on May 22, 2026, due to the untimely filing of its 2025 Annual Report on Form 20-F. This follows the company's recent regaining of compliance for its 2024 Annual Report and Q2 2025 interim financials by May 8, 2026, which placed it under a one-year mandatory panel monitor. Sinovac has requested a hearing before the Nasdaq Panel, which temporarily stays the suspension of its securities.
Key Highlights
- Sinovac received a Nasdaq delist determination letter on May 22, 2026, for not timely filing its 2025 Annual Report on Form 20-F.
- The company had previously regained compliance with Nasdaq's periodic filing rules by May 8, 2026, for its 2024 Annual Report and Q2 2025 interim financials.
- Sinovac is subject to a mandatory Nasdaq panel monitor for one year from May 20, 2026.
- Due to the late 2025 Annual Report, Nasdaq stated the company no longer complies with the Periodic Filing Rule.
- Sinovac requested a hearing before the Nasdaq Panel on May 29, 2026.
- The hearing request automatically stays the suspension of the company's securities for 22 calendar days from the Staff Determination date.
Price Impact
More from SVA